Rosa Faner

List of Publications by Year
in descending order

102 papers	4,611 citations	147726 31 h-index	110317 64 g-index
105 all docs	105 docs citations	105 times ranked	6670 citing authors

#	Article	IF	Citations
1	Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2015, 373, 111-122.	13.9	974
2	Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?. Lancet Respiratory Medicine,the, 2020, 8, 436-438.	5.2	314
3	Lung function in early adulthood and health in later life: a transgenerational cohort analysis. Lancet Respiratory Medicine,the, 2017, 5, 935-945.	5.2	235
4	Abnormal Lung Aging in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 306-313.	2.5	220
5	Lung function trajectories in health and disease. Lancet Respiratory Medicine,the, 2019, 7, 358-364.	5.2	213
6	The microbiome in respiratory medicine: current challenges and future perspectives. European Respiratory Journal, 2017, 49, 1602086.	3.1	194
7	Precision medicine in airway diseases: moving to clinical practice. European Respiratory Journal, 2017, 50, 1701655.	3.1	151
8	Lessons from ECLIPSE: a review of COPD biomarkers. Thorax, 2014, 69, 666-672.	2.7	125
9	Network Analysis of Lung Transcriptomics Reveals a Distinct B-Cell Signature in Emphysema. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1242-1253.	2.5	99
10	Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of geneâ€“environment interactions across the lifespan. Lancet Respiratory Medicine,the, 2022, 10, 512-524.	5.2	93
11	What does endotyping mean for treatment in chronic obstructive pulmonary disease?. Lancet, The, 2017, 390, 980-987.	6.3	78
12	Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1078-1085.	2.5	78
13	Association of an SNP with intrathymic transcription of TSHR and Graves' disease: a role for defective thymic tolerance. Human Molecular Genetics, 2011, 20, 3415-3423.	1.4	74
14	Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Preâ€“Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 275-287.	2.5	72
15	COPD 2020: changes and challenges. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L879-L883.	1.3	66
16	Network medicine, multimorbidity and the lung in the elderly. European Respiratory Journal, 2014, 44, 775-788.	3.1	63
17	Personalized Respiratory Medicine: Exploring the Horizon, Addressing the Issues. Summary of a BRN-AJRCCM Workshop Held in Barcelona on June 12, 2014. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 391-401.	2.5	61
18	Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype. European Respiratory Journal, 2018, 51, 1702146.	3.1	60

#	Article	IF	Citations
19	Systemic Inflammation and Comorbidities in Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2012, 9, 43-46.	3.5	58
20	Network medicine analysis of COPD multimorbidities. Respiratory Research, 2014, 15, 111.	1.4	48
21	The inflammasome pathway in stable COPD and acute exacerbations. ERJ Open Research, 2016, 2, 00002-2016.	1.1	47
22	COPD beyond smoking: new paradigm, novel opportunities. Lancet Respiratory Medicine,the, 2018, 6, 324-326.	5.2	47
23	ZNRD1 (Zinc Ribbon Domainâ€“Containing 1) Is a Host Cellular Factor That Influences HIVâ€1 Replication and Disease Progression. Clinical Infectious Diseases, 2010, 50, 1022-1032.	2.9	42
24	Biomarkers, the control panel and personalized <scp>COPD</scp> medicine. Respirology, 2016, 21, 24-33.	1.3	42
25	Systemic Inflammatory Response to Smoking in Chronic Obstructive Pulmonary Disease: Evidence of a Gender Effect. PLoS ONE, 2014, 9, e97491.	1.1	40
26	Immune response in chronic obstructive pulmonary disease. Expert Review of Clinical Immunology, 2013, 9, 821-833.	1.3	39
27	Multi-level differential network analysis of COPD exacerbations. European Respiratory Journal, 2017, 50, 1700075.	3.1	38
28	Factors Associated with Low Lung Function in Different Age Bins in the General Population. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 292-296.	2.5	36
29	Lung Function sequelae in COVID-19 Patients 3 Months After Hospital Discharge. Archivos De Bronconeumologia, 2021, 57, 59-61.	0.4	36
30	From systems biology to P4 medicine: applications in respiratory medicine. European Respiratory Review, 2018, 27, 170110.	3.0	35
31	Multi-level immune response network in mild-moderate Chronic Obstructive Pulmonary Disease (COPD). Respiratory Research, 2019, 20, 152.	1.4	34
32	ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations. European Respiratory Journal, 2022, 59, 2102006.	3.1	34
33	Time for a change: anticipating the diagnosis and treatment of COPD. European Respiratory Journal, 2020, 56, 2002104.	3.1	33
34	Cellular Senescence in Lung Fibrosis. International Journal of Molecular Sciences, 2021, 22, 7012.	1.8	33
35	Molecular and clinical diseasome of comorbidities in exacerbated COPD patients. European Respiratory Journal, 2015, 46, 1001-1010.	3.1	32
36	Modified mesenchymal stem cells using miRNA transduction alter lung injury in a bleomycin model. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 313, L92-L103.	1.3	32

#	Article	IF	Citations
37	Integrative Genomics of Emphysema-Associated Genes Reveals Potential Disease Biomarkers. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 411-418.	1.4	28
38	Relationship between the respiratory microbiome and the severity of airflow limitation, history of exacerbations and circulating eosinophils in COPD patients. BMC Pulmonary Medicine, 2019, 19, 112.	0.8	28
39	CCL4L Polymorphisms and CCL4/CCL4L Serum Levels Are Associated with Psoriasis Severity. Journal of Investigative Dermatology, 2011, 131, 1830-1837.	0.3	25
40	Chronic Airway Diseases Early Stratification (CADSET): a new ERS Clinical Research Collaboration. European Respiratory Journal, 2019, 53, 1900217.	3.1	25
41	Copy number variation in the CCL4L gene is associated with susceptibility to acute rejection in lung transplantation. Genes and Immunity, 2009, 10, 254-259.	2.2	24
42	Precision medicine in COPD exacerbations. Lancet Respiratory Medicine,the, 2018, 6, 657-659.	5.2	23
43	Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge. Respiratory Research, 2022, 23, 37.	1.4	23
44	HLA-B27 genotyping by Fluorescent Resonance Emission Transfer (FRET) probes in real-time PCR. Human Immunology, 2004, 65, 826-838.	1.2	22
45	Reassessing the role of HLAâ€ÐRB3 Tâ€cell responses: Evidence for significant expression and complementary antigen presentation. European Journal of Immunology, 2010, 40, 91-102.	1.6	21
46	Hospitalizations due to exacerbations of COPD: A big data perspective. Respiratory Medicine, 2018, 145, 219-225.	1.3	21
47	Phenotypic characterisation of early COPD: a prospective caseâ€“control study. ERJ Open Research, 2020, 6, 00047-2020.	1.1	21
48	Multilevel, Dynamic Chronic Obstructive Pulmonary Disease Heterogeneity. A Challenge for Personalized Medicine. Annals of the American Thoracic Society, 2016, 13, S466-S470.	1.5	20
49	Population structure in copy number variation and SNPs in the CCL4L chemokine gene. Genes and Immunity, 2008, 9, 279-288.	2.2	19
50	An investigation of the resolution of inflammation (catabasis) in COPD. Respiratory Research, 2012, 13, 101.	1.4	19
51	Spirometry: A practical lifespan predictor of global health and chronic respiratory and non-respiratory diseases. European Journal of Internal Medicine, 2021, 89, 3-9.	1.0	19
52	Changes in lung function in European adults born between 1884 and 1996 and implications for the diagnosis of lung disease: a cross-sectional analysis of ten population-based studies. Lancet Respiratory Medicine,the, 2022, 10, 83-94.	5.2	19
53	The Overlap of Lung Tissue Transcriptome of Smoke Exposed Mice with Human Smoking and COPD. Scientific Reports, 2018, 8, 11881.	1.6	18
54	Proyecto de biomarcadores y perfiles clÃnicos personalizados en la enfermedad pulmonar obstructiva crÃ³nica (proyecto BIOMEPOC). Archivos De Bronconeumologia, 2019, 55, 93-99.	0.4	18

#	Article	IF	Citations
55	Single cell RNA sequencing identifies IGFBP5 and QKI as ciliated epithelial cell genes associated with severe COPD. Respiratory Research, 2021, 22, 100.	1.4	18
56	Fibrinogen and COPD: Now what?. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 2, 1-3.	0.5	16
57	HLA Distribution in COPD Patients. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 138-146.	0.7	15
58	Development of a new HLA-DRB real-time PCR typing method. Human Immunology, 2005, 66, 85-91.	1.2	14
59	Risk Factors and Relation with Mortality of a New Acquisition and Persistence of Pseudomonas aeruginosa in COPD Patients. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2021, 18, 333-340.	0.7	14
60	<scp>HLAâ€ÐQ2</scp>/<scp>DQ8</scp> and <scp>HLAâ€ÐQB1</scp>*02 homozygosity typing by realâ€time polymerase chain reaction for the assessment of celiac disease genetic risk: evaluation of a Spanish celiac population. Tissue Antigens, 2014, 84, 545-553.	1.0	13
61	Smoking Impairs the Immunomodulatory Capacity of Lung-Resident Mesenchymal Stem Cells in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2019, 61, 575-583.	1.4	13
62	Lung DNA Methylation in Chronic Obstructive Pulmonary Disease: Relationship with Smoking Status and Airflow Limitation Severity. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 129-134.	2.5	13
63	Spirometric phenotypes from early childhood to young adulthood: a Chronic Airway Disease Early Stratification study. ERJ Open Research, 2021, 7, 00457-2021.	1.1	13
64	Network analysis: a way forward for understanding COPD multimorbidity. European Respiratory Journal, 2015, 46, 591-592.	3.1	12
65	Distribution, temporal stability and association with all-cause mortality of the 2017 GOLD groups in the ECLIPSE cohort. Respiratory Medicine, 2018, 141, 14-19.	1.3	12
66	Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19. Lancet Respiratory Medicine,the, 2021, 9, 682-683.	5.2	12
67	Lung function trajectory and biomarkers in the Tasmanian Longitudinal Health Study. ERJ Open Research, 2021, 7, 00020-2021.	1.1	11
68	Real-Time PCR Using Fluorescent Resonance Emission Transfer Probes for HLA-B Typing. Human Immunology, 2006, 67, 374-385.	1.2	10
69	Low birth weight as a potential risk factor for severe COVID-19 in adults. Scientific Reports, 2021, 11, 2909.	1.6	10
70	Chronic bronchial infection and incident cardiovascular events in chronic obstructive pulmonary disease patients: A longâ€term observational study. Respirology, 2021, 26, 776-785.	1.3	10
71	Do sputum or circulating blood samples reflect the pulmonary transcriptomic differences of COPD patients? A multi-tissue transcriptomic network META-analysis. Respiratory Research, 2019, 20, 5.	1.4	9
72	Reduced airway levels of fatty-acid binding protein 4 in COPD: relationship with airway infection and disease severity. Respiratory Research, 2020, 21, 21.	1.4	9

#	Article	IF	Citations
73	Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial. European Respiratory Journal, 2022, 59, 2103036.	3.1	9
74	Bone marrow characterization in COPD: a multi-level network analysis. Respiratory Research, 2018, 19, 118.	1.4	8
75	EARLY COPD: determinantes de la aparicIÃ³n y progresiÃ³n de la enfermedad pulmonar obstructiva crÃ³nica en adultos jÃ³venes. Protocolo de un estudio caso-control con seguimiento. Archivos De Bronconeumologia, 2019, 55, 312-318.	0.4	8
76	3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD. European Respiratory Journal, 2021, 58, 2102168.	3.1	8
77	High resolution definition of HLAâ€DRB haplotypes by a simplified microsatellite typing technique. Tissue Antigens, 2009, 74, 486-493.	1.0	7
78	Characterization, localization and comparison of c-Kit+ lung cells in never smokers and smokers with and without COPD. BMC Pulmonary Medicine, 2018, 18, 123.	0.8	6
79	How to Define Early Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 973-973.	2.5	6
80	Chronic Obstructive Pulmonary Disease Pathogenesis. Clinics in Chest Medicine, 2020, 41, 307-314.	0.8	6
81	Towards a global initiative for fibrosis treatment (GIFT). ERJ Open Research, 2017, 3, 00106-2017.	1.1	5
82	The Changing Landscape of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 978-981.	2.5	5
83	The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease. Archivos De Bronconeumologia, 2019, 55, 93-99.	0.4	5
84	Telomere Length but Not Mitochondrial DNA Copy Number Is Altered in Both Young and Old COPD. Frontiers in Medicine, 2021, 8, 761767.	1.2	5
85	The EASI model: A first integrative computational approximation to the natural history of COPD. PLoS ONE, 2017, 12, e0185502.	1.1	4
86	Determinants of the Appearance and Progression of Early-Onset Chronic Obstructive Pulmonary Disease in Young Adults. A Caseâ€“Control Study With Follow-Up. Archivos De Bronconeumologia, 2019, 55, 312-318.	0.4	4
87	When Harry Met Sally, or When Machine Learning Met Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 263-265.	2.5	4
88	Liver epigenome changes in patients with hepatopulmonary syndrome: A pilot study. PLoS ONE, 2021, 16, e0245046.	1.1	4
89	<scp>CT</scp> in <scp>COPD</scp>: To be or not to be. Respirology, 2022, 27, 258-259.	1.3	4
90	COPD: algorithms and clinical management. European Respiratory Journal, 2017, 50, 1701733.	3.1	3

#	Article	IF	Citations
91	Global lung health: the dangers of mild lung function impairment. The Lancet Global Health, 2019, 7, e542-e543.	2.9	3
92	Transitioning from infancy to adulthood: a black box full of opportunities. European Respiratory Journal, 2021, 57, 2003997.	3.1	3
93	MÃ¡s alla del binomio EPOC-tabaco: nuevas oportunidades para la prevenciÃ³n y tratamiento precoz de la enfermedad. Medicina ClÃnica, 2022, 159, 33-39.	0.3	3
94	Building Strong Neighborhoods in the Lung with a Little Help from My Mesenchymal Stem Cells. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1176-1178.	2.5	2
95	Molecular Interactions of SARS-CoV-2 in Lung Tissue of Patients with Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2021, 18, 1922-1924.	1.5	2
96	Lung aging and senescence in health and disease. , 2022, , 61-80.		1
97	Predicting Early Hospital Readmissions in COPD Patients Using an Electronic Nose. Archivos De Bronconeumologia, 2022, 58, 663-665.	0.4	1
98	SARS-CoV-2 T-cell response in COVID-19 convalescent patients with and without lung sequelae. ERJ Open Research, 2022, 8, 00706-2021.	1.1	1
99	Can Circulating Biomarkers Identify Different FEV ₁ Trajectories of COPD Patients?. SSRN Electronic Journal, 0, , .	0.4	0
100	Tabaco y alteraciones intersticiales: Â¿una asociaciÃ³n plausible?. Archivos De Bronconeumologia, 2020, 56, 422-423.	0.4	0
101	Organizing Pneumonia and COVID-19. SSRN Electronic Journal, 0, , .	0.4	0
102	Beyond the COPD-tobacco binomium: New opportunities for the prevention and early treatment of the disease. Medicina ClÃnica (English Edition), 2022, 159, 33-39.	0.1	0